运动障碍的神经影像学与治疗学
Neuroimaging and therapeutics in movement disorders.
作者信息
Eckert Thomas, Eidelberg David
机构信息
Department of Neurology II and Psychiatry, University of Magdeburg, Germany.
出版信息
NeuroRx. 2005 Apr;2(2):361-71. doi: 10.1602/neurorx.2.2.361.
Abstract
In this review, we discuss the role of neuroimaging in assessing treatment options for movement disorders, particularly Parkinson's disease (PD). Imaging methods to assess dopaminergic function have recently been applied in trials of potential neuroprotective agents. Other imaging methods using regional metabolism and/or cerebral perfusion have been recently introduced to quantify the modulation of network activity as an objective marker of the treatment response. Both imaging strategies have provided novel insights into the mechanisms underlying a variety of pharmacological and stereotaxic surgical treatment strategies for PD and other movement disorders.
摘要
在本综述中，我们讨论神经影像学在评估运动障碍，特别是帕金森病（PD）治疗方案中的作用。评估多巴胺能功能的成像方法最近已应用于潜在神经保护剂的试验中。最近还引入了其他利用区域代谢和/或脑灌注的成像方法，以量化网络活动的调节，作为治疗反应的客观指标。这两种成像策略都为PD和其他运动障碍的各种药物和立体定向手术治疗策略的潜在机制提供了新的见解。
相似文献
1
Neuroimaging and therapeutics in movement disorders.
NeuroRx. 2005 Apr;2(2):361-71. doi: 10.1602/neurorx.2.2.361.
2
[Functional neuroimaging in movement disorders].
Orv Hetil. 2001 Oct 28;142(43):2347-55.
3
Imaging studies in movement disorders.
Semin Nucl Med. 2003 Apr;33(2):105-13. doi: 10.1053/snuc.2003.127303.
4
Supplement neuroimaging movement disorders.
Mov Disord. 2009;24 Suppl 2:S655. doi: 10.1002/mds.22770.
5
Neurodegenerative movement disorders: the contribution of functional imaging.
Curr Opin Neurol. 2004 Aug;17(4):459-66. doi: 10.1097/01.wco.0000137538.84115.3c.
6
Network biomarkers for the diagnosis and treatment of movement disorders.
Neurobiol Dis. 2009 Aug;35(2):141-7. doi: 10.1016/j.nbd.2008.09.026. Epub 2008 Nov 1.
7
Pathophysiology of movement disorders studied using PET.
J Neural Transm Suppl. 1997;50:39-46. doi: 10.1007/978-3-7091-6842-4_5.
8
Movement disorders: understanding clinical trials.
Lancet Neurol. 2005 Jan;4(1):5-6. doi: 10.1016/S1474-4422(04)00945-7.
9
Imaging Transplantation in Movement Disorders.
Int Rev Neurobiol. 2018;143:213-263. doi: 10.1016/bs.irn.2018.10.002. Epub 2018 Nov 3.
10
Imaging end points for monitoring neuroprotection in Parkinson's disease.
Ann Neurol. 2003;53 Suppl 3:S110-8; discussion S118-9. doi: 10.1002/ana.10480.
引用本文的文献
1
Distinguishing patients with Parkinson's disease subtypes from normal controls based on functional network regional efficiencies.
PLoS One. 2014 Dec 22;9(12):e115131. doi: 10.1371/journal.pone.0115131. eCollection 2014.
2
Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease.
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2209-18. doi: 10.1007/s00259-011-1874-1. Epub 2011 Jul 9.
3
Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease.
Mov Disord. 2009;24 Suppl 2(0 2):S725-31. doi: 10.1002/mds.22541.
4
Prodromal non-motor symptoms of Parkinson's disease.
Neuropsychiatr Dis Treat. 2007 Feb;3(1):145-52. doi: 10.2147/nedt.2007.3.1.145.
5
Abnormal regional brain function in Parkinson's disease: truth or fiction?
Neuroimage. 2009 Apr 1;45(2):260-6. doi: 10.1016/j.neuroimage.2008.09.052. Epub 2008 Oct 18.
6
Neuroimaging and transcranial ultrasonography in Parkinson's disease.
Curr Neurol Neurosci Rep. 2008 Jul;8(4):297-303. doi: 10.1007/s11910-008-0046-6.
7
Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease.
J Neurosci. 2008 Apr 16;28(16):4201-9. doi: 10.1523/JNEUROSCI.0582-08.2008.
8
Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19559-64. doi: 10.1073/pnas.0706006104. Epub 2007 Nov 27.
9
STN-stimulation in Parkinson's disease restores striatal inhibition of thalamocortical projection.
Hum Brain Mapp. 2009 Jan;30(1):112-21. doi: 10.1002/hbm.20486.
10
Assessment of the progression of Parkinson's disease: a metabolic network approach.
Lancet Neurol. 2007 Oct;6(10):926-32. doi: 10.1016/S1474-4422(07)70245-4.
本文引用的文献
1
Single-photon emission computed tomography in neurotherapeutics.
NeuroRx. 2005 Apr;2(2):237-49. doi: 10.1602/neurorx.2.2.237.
2
Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.
NeuroRx. 2005 Apr;2(2):226-36. doi: 10.1602/neurorx.2.2.226.
3
Foundations of advanced magnetic resonance imaging.
NeuroRx. 2005 Apr;2(2):167-96. doi: 10.1602/neurorx.2.2.167.
4
The role of radiotracer imaging in Parkinson disease.
Neurology. 2005 Jan 25;64(2):208-15. doi: 10.1212/01.WNL.0000149403.14458.7F.
5
Levodopa and the progression of Parkinson's disease.
N Engl J Med. 2004 Dec 9;351(24):2498-508. doi: 10.1056/NEJMoa033447.
6
PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences.
Neuroimage. 2004 Sep;23(1):1-16. doi: 10.1016/j.neuroimage.2004.04.039.
7
Parkinson's disease-like presentation of multiple system atrophy with poor response to STN stimulation: a clinicopathological case report.
Mov Disord. 2004 Aug;19(8):973-7. doi: 10.1002/mds.20108.
8
Microstructural white matter changes in carriers of the DYT1 gene mutation.
Ann Neurol. 2004 Aug;56(2):283-6. doi: 10.1002/ana.20177.
9
Onset and rate of striatal atrophy in preclinical Huntington disease.
Neurology. 2004 Jul 13;63(1):66-72. doi: 10.1212/01.wnl.0000132965.14653.d1.
10
Executive processes in Parkinson's disease: FDG-PET and network analysis.
Hum Brain Mapp. 2004 Jul;22(3):236-45. doi: 10.1002/hbm.20033.
Zotero 插件